Australia's most trusted
source of pharma news
Friday, 23 May 2025
Posted 22 May 2025 PM
Two of three newly registered RSV vaccines have been slapped with new safety information on the low risk of individuals 60 years and older contracting Guillain-Barre syndrome (GBS) following vaccination.
The decision follows a focused signal investigation, which commenced in November 2024 to review US data presented at the Advisory Committee on Immunisation Practices October 2024 meeting.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.